GlassScriptPhysician profile
Joshua N Daniel
NPI 1841647823
$41,999.11
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $187 · 2021: $27K · 2022: $15K · 2023: $15.87 · 2024: $25.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $41.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $41.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39,666.66 | 2021-2023 | Botox |
| Allergan, INC. | $2,019.98 | 2019-2021 | |
| Amgen INC. | $51.59 | 2019-2024 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $50.43 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $40.76 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Avanir Pharmaceuticals, INC. | $27.64 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $27.34 | 2021 | |
| Ucb, INC. | $14.76 | 2019 | |
| Sk Life Science, INC. | $13.26 | 2022 | |
| Lilly USA, LLC | $12.60 | 2019 | |
| Amneal Pharmaceuticals LLC | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.